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The identification of activated T-lymphocytes restricted to myelin-derived immunogenic 
peptides in multiple sclerosis (MS) and aquaporin-4 water channel in neuromyelitis 
optica (NMO) in the blood of patients opened the possibility for developing highly 
selective and disease-specific therapeutic approaches. Antigen presenting cells and in 
particular dendritic cells (DCs) represent a strategy to inhibit pro-inflammatory T helper 
cells. DCs are located in peripheral and lymphoid tissues and are essential for homeo-
stasis of T  cell-dependent immune responses. The expression of a particular set 
of receptors involved in pathogen recognition confers to DCs the property to initiate 
immune responses. However, in the absence of danger signals different DC subsets 
have been revealed to induce active tolerance by inducing regulatory T cells, inhibiting 
pro-inflammatory T helper cells responses or both. Interestingly, several protocols to 
generate clinical-grade tolerogenic DC (Tol-DC) in  vitro have been described, offering 
the possibility to restore the homeostasis to central nervous system-related antigens. In 
this review, we discuss about different DC subsets and their role in tolerance induction, 
the different protocols to generate Tol-DCs and preclinical studies in animal models as 
well as describe recent characterization of Tol-DCs for clinical application in autoimmune 
diseases and in particular in MS and NMO patients. In addition, we discuss the clinical 
trials ongoing based on Tol-DCs to treat different autoimmune diseases.
Keywords: tolerogenic dendritic cells, dendritic cells, immunotherapy, immunosuppression, multiple sclerosis, 
Neuromyleitis optica 
iNTRODUCTiON
Multiple Sclerosis (MS) is a chronic autoimmune inflammatory disease affecting the central ner­
vous system (CNS) (1). Nowadays, there are 2.3 million affected people worldwide, being the most 
frequent age of diagnosis between 20 and 40 years old (2). Additionally, the studies determine that 
MS is more frequent in women and in northern locations. There are different subtypes of MS which 
Abbreviations: APCs, antigen presenting cells; APL, altered peptide ligand; AQP4, aquaporin­4; CNS, central nervous system; 
DCs, dendritic cells; Mo­DCs, monocyte­derived DCs; MS, multiple sclerosis; NMO, neuromyelitis optica; PPMS, primary­
progressive MS; RA, rheumatoid arthritis; RRMS, relapsing­remitting MS; SPMS, secondary­progressive MS; Tol­DCs, 
tolerogenic DCs.
TAble 1 | 2010 Mc Donald criteria for multiple sclerosis (MS) diagnosis (4).
Clinical presentation Additional data needed for MS diagnosis
2 or more attacks; objective clinical evidence  
of 2 or more lesions or objective clinical  
evidence of 1 lesion with reasonable historical 
evidence of a prior attack
None
2 or more attacks; objective clinical  
evidence of 1 lesion
Dissemination in space, demonstrated by:
1 or more T2 lesions in at least 2 of 4 MS-typical regions of the central nervous system (CNS) (periventricular,  
juxtacortical, infratentorial, or spinal cord); or await a further clinical attack implicating a different CNS site
1 attack; objective clinical evidence  
of 2 or more lesions
Dissemination in time, demonstrated by: 
simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing lesions at any time;  
or A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference  
to a baseline scan; or await a second clinical attack
1 attack; objective clinical evidence  
of 1 lesion (clinically isolated syndrome)
Dissemination in space and time, demonstrated by: 
for DIS: 1 or more T2 lesion in at least 2 of 4 MS-typical regions of the CNS (periventricular, juxtacortical,  
infratentorial, or spinal cord); or await a second clinical attack implicating a different CNS site; and
for DIT: simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing lesions  
at any time; or a new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its  
timing with reference to a baseline scan; or Await a second clinical attack
Insidious neurological progression
suggestive of MS (PPMS)
1 year of disease progression (retrospectively or prospectively determined) plus 2 of 3 of the following criteria:
 1. evidence for DIS in the brain based on 1 or more T2 lesions in the MS-characteristic (periventricular,  
juxtacortical, or infratentorial) regions
 2. evidence for DIS in the spinal cord based on 2 or more T2 lesions in the cord
 3. positive CSF (isoelectric focusing evidence of oligoclonal bands and/or elevated IgG index)
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are based on their clinical phenotype (3). These subtypes are: 
The primary­progressive MS (PPMS) which is a disabling subtype 
from the beginning, the relapsing­remitting type (RRMS) that 
is characterized by clinical relapses without progression of disabi­
lity and finally, the secondary­progressive subtype that appears 
about 20 years after RRMS.
The MS diagnosis is summarized in the revised 2010 Mc Donald 
criteria which is included in Table 1 (4). Although the cause of 
the immune deregulation is unknown, there are evidences that 
implicate Th1 and Th17 lymphocytes in the pathophysiology of 
MS (5–10). Furthermore, it was supported by studies performed 
in experimental models of MS either knocking out or blocking 
using monoclonal antibodies for IL­17 or IL­23 resulted in a 
suppression of the activity of this disease (11, 12). Other authors 
have described that memory T­cells are activated in the periphery 
by different processes that can be promoted by environmental or 
genetic factors. These activated cells cross the blood–brain bar­
rier, penetrate to CNS where they are locally reactivated (9, 13).
First­line therapies for MS include injectable treatments such 
as IFN­β, and glatiramer as well as oral therapies such as terif­
lunomide and dimethyl­fumarate. Second­line therapies include 
fingolimod, and the intravenous natalizumab, which present higher 
levels of efficacy in reducing the relapse rate; however, it has poten­
tial severe side effects. Moreover, Alentuzumab, Cladribine, and 
Ocrelizumab were recently added as approved therapies, and they 
are in progress of being defined in the pyramid of the MS therapy. 
All these mentioned treatments are systemic immunomodulatory 
or immunosuppressive treatments with risks of adverse events.
Neuromyelitis optica (NMO) is an inflammatory disease affec­
ting the CNS (14) with similar physiopathology as MS, but is 
considered an autoimmune astrocytopathy. NMO is a rare disease 
which presents with incidence between 0.05 and 0.4/100,000 
(15, 16). About 70% of the patients diagnosed with NMO shows 
the presence of anti­aquaporin­4 (AQP4) antibody as well as 
specific T­lymphocytes in the bloodstream or CSF which suggest 
the pro­inflammatory role of these cells (17). Importantly, the 
detection of anti­AQP4 antibodies is related with more severe 
disease (14). Recently, among seronegative patients, anti­(MOG) 
antibodies have been described as the pathological antibody (18). 
This disease has its own international consensus diagnostic criteria 
(19), defining the NMO spectrum disorder (NMOSD) concept 
(Table 2). Different MS drugs such as natalizumab or finolimob 
have been evaluated in NMO resulting in exacerbation of relapses 
(20). Immunomodulatory or immunossuppressant therapies are 
used for label in NMOSD (e.g., azathioprine, mycophenolate, 
cyclophosphamide, or rituximab) (21). Furthermore, several 
monoclonal antibodies are in clinical trials to evaluate their 
efficacy and safety, as tocilizumab, satralizumab, eculizumab, or 
aquapuromab for example (22). Based in the unmet need of 
achieving higher levels of efficacy and/or better safety profile, 
antigen­specific therapies are being considered as a potential 
treatment for MS and NMO (19).
DeNDRiTiC CellS (DCs)
Dendritic cells act as a link between innate and adaptive immune 
responses. Their main function is to capture and process exog­
enous antigens in the peripheral tissues to present them to T­cells 
after migration to the draining lymph nodes. In addition, they 
polarize immune responses by promoting both pro­ and anti­
inflammatory immune responses depending on the presence of 
danger signals associated to the antigens (Figure 1) (24, 25).
FigURe 1 | Dendritic cells can polarize immune response though promote 
both pro- and anti-inflammatory activities in response to different stimuli. 
Adapted from: O’Neil et al. (26). TLRs: toll-like receptors, HSP: Heat shock 
proteins.
TAble 2 | Neuromyelitis optica spectrum disorder diagnostic criteria from  
Ref. (23).
Diagnostic criteria for NMO spectrum disorder (NMOSD) with aquaporin-4 
(AQP4)-IgG.
 1. At least 1 core clinical characteristic.
 2. Positive test for AQP4-IgG using best available detection  
method (cell-based assay strongly recommended).
 3. Exclusion of alternative diagnoses.
Diagnostic criteria for NMOSD without AQP4-IgG or NMOSD with unknown 
AQP4-IgG status.
 1. At least 2 core clinical characteristics occurring as a result of one or more 
clinical attacks and meeting all of the following requirements:
 (a) At least 1 core clinical characteristic must be optic neuritis, acute myelitis 
with LETM, or area postrema syndrome
 (b) Dissemination in space (2 or more different core clinical characteristics)
 (c) Fulfillment of additional MRI requirements, as applicable
 2. Negative tests for AQP4-IgG using best available detection method,  
or testing unavailable
 3. Exclusion of alternative diagnoses
Core clinical characteristics.
 1. Optic neuritis.
 2. Acute myelitis.
 3. Area postrema syndrome: unexplained hiccups or nausea and vomiting.
 4. Acute brainstem syndrome.
 5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with 
NMOSD-typical diencephalic MRI lesions.
 6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions.
Additional MRI requirements for NMOSD without AQP4-IgG and NMOSD  
with unknown AQP4-IgG status.
 1. Acute optic neuritis: requires brain MRI showing (a) normal findings or only 
nonspecific white matter lesions, OR (b) optic nerve MRI with T2-hyperintense 
lesion or T1-weighted gadolinium-enhancing lesion extending over 1/2 optic 
nerve length or involving optic chiasm.
 2. Acute myelitis: intramedullary MRI lesion extending over 3 contiguous 
segments (LETM) OR 3 contiguous segments of focal spinal cord atrophy in 
patients with history compatible with acute myelitis.
 3. Area postrema syndrome: dorsal medulla/area postrema lesions.
 4. Acute brainstem syndrome: periependymal brainstem lesions.
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Dendritic cells are located in peripheral tissues (skin and 
mucosa) and remain in an immature state (iDCs) until they interact 
with the antigens. After cells activation, DCs initiate a maturation 
process in which mature DCs (mDCs) lose capacities for antigen 
uptake in favor of acquiring stimulatory properties for the activa­
tion of naïve T­cells and the development of effector T­cells (27). 
Maturation process involves different processes and physiological 
changes in DCs, which are illustrated in Figure 2 (28).
Due to their immunological functions and the availability of 
clinical­grade reagents, immunogenic DCs have been safely used 
in clinical trials to potentiate immune response against tumors 
or infectious diseases (30). However, only a few studies recently 
published have taken advantage of their specific tolerogenic 
properties to treat Type 1 diabetes, rheumatoid arthritis (RA) and 
Crohn’s disease patients (25, 31, 32).
HUMAN DCs SUbSeTS
Dendritic cells can be sub­classified based on anatomical location, 
origin, and function. In humans, different DC subsets have been 
identified in blood, spleen and skin and in non­lymphoid tissues. 
Each DC subset presents different specialization in T­cell priming 
and induction of immune responses, although their functions 
can partially overlap (33).
In peripheral blood, DCs that express Human Leukocyte 
Antigen—antigen D Related (HLA­DR) and lineage negative 
fraction are divided into two main groups: conventional myeloid 
DCs (cDCs) and non­conventional plasmacytoid DCs (pDC). 
Within myeloid DCs two main subsets have been identified 
based on their surface marker expression: CD1c/BDCA­1 cDCs 
and CD141/BDCA­3 cDCs. However, recently new DC subset 
classification has been described (CD16 and DC5) (23). Circu­
lating DCs represent a little fraction of total circulating peripheral 
blood mononuclear cells (PBMCs) as they account for less than 
1% of PBMCs (24, 34).
In the skin two different subsets of DCs can be found. Langerhans 
cells (LCs) which contributes to immune surveillance and CD14 
DCs, which are involved in tolerance induction (35, 36).
From all the different DC subsets above mentioned, the 
BDCA­1, pDCs, LCs, and CD14 have been described to gener­
ate both immunogenic and suppressive functions (Figure  3). 
BDCA­1 have the capacity to produce IL­10 in response to 
E. coli and potentially contribute to suppress immune responses. 
Recently, a particular subset of BDCA­1 (BDCA1­CD14+) has 
been shown to act as immunosuppressive cells in certain types of 
tumor environment and may hamper anti­cancer DCs vaccines 
(37, 38) Moreover, in an steady state, pDCs are able to induce 
tolerogenic immune responses by inducing T­cell anergy and 
promoting T­reg cells development. They have been found to be 
infiltrated in tumors activating Tr1 cells (33, 39, 40). LCs, apart 
from respond to intracellular pathogens and viruses under inflam­
matory conditions are in charge to maintain epidermal health 
and tolerance to commensals from the skin, while retaining the 
FigURe 3 | Dendritic cells subsets classification and their main properties. Adapted from: Cohn et al. (37). PRRs, pattern recognition receptors.
FigURe 2 | Maturation process of dendritic cells (DCs). Adapted from: Steinman et al. (29). LN, lymph nodes.
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ability to respond to selected pathogens (40–42). Finally CD14 
DCs also have the ability to generate T­regs through the elevated 
IL­10 production (43, 44).
To sum up, BDCA­1, pDCs, LCs, and CD14 have been shown 
to present immunoregulatory effects. However, deeper charac­
terization of this tolerogenic profile and mechanisms needs to be 
performed.
TOleROgeNiC DCs (Tol-DCs)  
AND MeCHANiSMS OF  
TOleRANCe iNDUCTiON
As described in the previous section, DCs play a crucial role in 
the initiation of immune responses and also in maintaining the 
immune tolerance. DCs present both foreign antigens as well as 
endogenous antigens derived from tissues. For this reason, the 
immune system is able to distinguish between innocuous and 
harmful antigens to avoid autoimmune or undesired immune 
responses (45). Several studies point that a key factor for DCs 
to initiate immunity or tolerance is the maturation stage of DCs 
(25). It is generally accepted that in absence of danger signals 
provided by infection or inflammation, DCs remain in an imma­
ture state which will induce tolerance by deleting or inducing 
apoptosis of self­antigen­specific T­cells (25, 46). However, other 
several mechanisms to explain how DCs induce tolerance have 
been proposed. Some authors have reported that low expression 
of MHC molecules and co­stimulatory receptors on DC surface 
fail to stimulate T­cells sufficiently, thus resulting in T­cell anergy 
(47–49). Currently, it has been demonstrated that the expression 
FigURe 4 | Mechanisms of tolerance induction by dendritic cells. Adapted from: Cabezón et al. (30).
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of single immunoglobulin IL­1 related receptor, which is lower in 
iDCs, has a role in maintain low levels of costimulatory mole cules 
and in the regulation of T­reg cell expansion (50). Furthermore, 
it is well established that the expression of certain molecules such 
as PD­L1 rather than promote activation signals to T­cells, they 
induce T­cell anergy (28, 51, 52). Moreover, some authors dem­
onstrated that suboptimal antigen presentation, together with 
indoleamine 2,3­dioxygenase (IDO) or Fas­L (CD95L) expres­
sion by DCs leads to inhibition of T­cell proliferation and T­cell 
deletion, respectively. Finally but not the least, the production of 
the potent anti­inflammatory cytokine IL­10 by DCs is crucial 
for peripheral tolerance induction. IL­10 acts on a wide variety of 
immune cells and it has been clearly involved in T­reg as well as 
Tr1 induction (38). In the steady state, peripheral T­reg cells rise 
from peripheral CD4+CD25−FOXP3− T cells that are exposed to 
antigen in the presence of transforming growth factor­β as well 
as IL­10 without IL­6 or IL­1β, which promotes the up­regulation 
of FOXP3 (17) (Figure 4). Recent developments carried on by 
Agrawal et al., have shown that C­lectin receptor (CLEC­2) upre­
gulation in DCs, is associated with T­reg induction. Moreover, 
they have also described that platelet growth factor is able to 
induce IL­10 production by DCs and in consequence T­reg cell 
induction (53).
In consequence, major efforts have been focused on in vitro 
generation of Tol­DCs. In this regard, different immunosup­
pressive drugs, such as corticosteroids, cyclosporine, tacrolimus, 
rapamycin, deoxyspergualin, vitamin D3 (vitD3), mycophenolate 
mofetil, and sanglifehrin A, have been successfully used to modu­
late DCs differentiation and function. Thus, several protocols that 
include the generation of monocyte­derived DCs in the presence 
of corticosteroids and a defined maturation cytokine cocktail 
(including TNF­α, IL­1β, IL­6, and PGE2) or lipopolysaccharide 
(LPS) activation in order to boost their tolerogenic properties, 
have been described to generate Tol­DCs in vitro (54, 55).
Tolerogenic DCs present an intermediate phenotype between 
iDCs and mDCs regarding costimulatory molecules, a pronounced 
shift toward anti­inflammatory versus pro­inflammatory cyto­
kine production (high amounts of IL­10 versus low levels of 
IL­12p70 and IL­23) and a reduced capacity to stimulate T­cells 
response. In addition Tol­DCs present an increment of IL­10 
production upon Gram­negative bacterial interaction which rep­
resents a relevant factor to induce tolerance due to the potent anti­ 
inflammatory role of IL­10 (Figure 5) (56–58).
The role of in vitro generated Tol­DCs as potential immuno­
modulatory and immunosuppressive agents have been evaluated 
by different groups (44, 60, 61). The first experimental data to 
objectify the potential of human Tol­DC to induce tolerance in 
MS, was the induction of T­cell hyporesponsiveness by Tol­DC 
from MS patients. The results obtained shown that only Tol­DCs 
(vitD3) derived from RRMS patients, induced hyporesponsive­
ness in autologous antigen­specific T­cells restricted to myelin­
derived peptides and produced higher levels of IL­10 and reduced 
levels of TNF­α compared to healthy controls, making the tolero­
genic potential of these autologous Tol­DCs may be an effective 
tool to re­establish tolerance in RRMS patients and set up the 
basis for the ongoing clinical trials (62). In addition, a critical 
consideration for Tol­DC application in immunotherapy is the 
phenotype stability once the cells are injected into the patients. 
It has been demonstrated that in vitro generated Tol­DCs have a 
stable tolerogenic profile after LPS stimulation as they produce 
higher amounts of IL­10 and as well as they are able to induce 
antigen­specific T­cell hyporesponsiveness (58, 63).
FigURe 5 | Comparison between iDCs, tolerogenic DCs and mature DCs properties. Adapted from: Hubo et al. (59).
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In summary, Tol­DCs generated ex vivo using immunosup­
pressive agents, induced T  regulatory cells through different 
mechanism such as lower expression of co stimulatory molecules, 
expression of inhibitory receptors and IL­10 production.
Tol-DC Therapy in the Animal Model of MS
Animal models are the first step in the development of new 
therapies, and antigen­specific therapies are not an exception 
to this rule. Over the past several decades animal models have 
been used to understand different aspects of human MS. There 
are three different animal models of MS that are the most com­
monly used: (1) the experimental autoimmune encephalomyelitis 
(EAE), (2) viral induced models, and (3) toxin­induced models 
of demyelination (6).
In addition to the in  vitro demonstration of the capacity of 
Tol­DC to induce immune tolerance, the role of Tol­DCs has 
been evaluated in the EAE model. The critical role of mDCs and 
pDCs in the chronic pathogenesis of EAE in Lewis rats described 
by Miller and colleagues makes this model extremely relevant 
to study positive and negative regulatory pathways involved in 
MS and other chronic autoimmune diseases (64). Wang et  al. 
demonstrated the involvement of CD11b+ and CD11c+ DCs in 
the generation of both T­regs and Tr1 cells, by depleting DCs they 
observed that tolerance effect disappeared (65). In consequence, 
the induction of DCs with a regulatory profile is a key mechanism 
underlying auto antigen­induced tolerance (64). It is interesting 
to highlight that studies performed in EAE induced in Lewis 
rats demonstrated that the maturation state as well as the route 
of administration influence on the induction of tolerance by 
these DCs which is in concordance with the in vitro performed 
studies (65, 66). Moreover, different authors have described 
that the administration of Tol­DCs generated with different 
immunosuppressive agents such as vitD3 or estriol induced a 
decrease of the incidence of the disease as well as they promoted 
the induction of regulatory T­cells though higher levels of IL­10 
production (63, 67).
In addition, other authors have performed comparisons regar­
ding the use of immunosuppressive oral drugs such as vitD3 
and (for 20 days after EAE induction) or pretreating DCs before 
EAE induction. The results obtained were similar in both cases: 
significant improvement of clinical severity and an increase of 
regulatory CD4+ Foxp3+ cells and increased IL­10 levels in lymph 
nodes from treated animals suggesting that DCs are the main 
target of tolerogenic effect of vitamin D. Some studies pointed 
out that in the absence of DCs during the priming process of 
autoreactive T­cells leads to a unidirectional deficiency of cell 
generation which results in a fulminant attack against CNS 
(65, 66, 68). Different studies using DCs to induce tolerance have 
been performed in EAE animal models of mice and rats and they 
are summarized in Table 3.
In addition, Tol­DCs have also been generated for another 
disease models such as type I diabetes T1D by using a combina­
tion of both dexamethasone and vitD3. This generated Tol­DCs 
presented a stable phenotype and a high capacity to induce T­reg 
cells (73). Moreover, other protocols, such as DC treatment with 
CD40, CD80, and CD86 antisense oligo nucleotides or even low 
doses of GM­CSF has also been reported although in some cases 
partial loss of tolerance have been reported.
The critical part is that after being culture, all generated Tol­DCs 
have to present different characteristics: (a) low levels of co stimu­
latory molecules, (b) stability when challenges with maturation 
stimuli and also produce IL­10, (c) lower activation of T­cells (73).
Overall, different protocols for Tol­DCs in preclinical studies 
has been shown to be beneficious to treat different autoimmune 
TAble 3 | Summary of tolerogenic DCs therapy in animal models (65, 67, 69, 70).
Animal model Dendritic cells injected Route of administration Reference
EAE in C57BL/6 mice 1 × 106 Intravenous Leng et al. (67)
EAE in C57BL/6J mice 1 × 106 Intravenous Mansilla et al. (63)
EAE in C57BL/6 mice 1–2 × 106 to 8–10 × 106 Intravenous Papenfuss et al. (67)
EAE in C57BL/6 mice 5 × 105 Subcutaneous or intraperitoneally Aghdami et al. (71)
EAE in Lewis rats 2 × 106 Subcutaneous or intravenous Zhang et al. (72)
EAE in Lewis rats 1 × 106 Subcutaneous Xiao et al. (66)
EAE, experimental autoimmune encephalomyelitis.
7
Flórez-Grau et al. Tol-DCs as new antigen-specific Therapy
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1169
diseases, in particular for EAE induction the use of vitD3 or 
corticosteroids is the most extended.
Therapeutic Application of Tol-DCs in Type 
i Diabetes, RA and Crohn’s Disease
Following the encouraging results obtained from different in vitro 
and preclinical studies in animal models, Tol­DCs are revealed as 
a promising therapy for autoimmune diseases and transplanta­
tion (32). Consequently, in 2011, the first phase I clinical trial 
with Tol­DCs was conducted at the University of Pittsburgh. The 
trial enrolled 10 insulin­dependent diabetic patients, and admin­
istrated control DCs to three patients and immunosuppressive 
DC (iRNA for CD40, CD80, and for CD86) to seven patients. The 
treatment was safe and well tolerated. There were no changes in 
insulin requirements, hematology assessments or blood immune 
cell population levels in both groups, showing a slight increase of 
CD4+CD25+++ FoxP3+ T cells in immunosuppressive DC group. 
All treated patients had normal immune responses to vaccination 
and alloantigen stimulation in vitro (74). Thus, a double­blinded, 
placebo­controlled cross­over phase II trial is planned to start in 
Diabetes mellitus type 1 in 24 patients with a recent onset of the 
disease, inducing tolerability of DC with antisense DNA targeting 
CD40, CD80, and CD86 (NCT02354911).
Among autoimmune arthritis, two trials have been published 
recently. In the first one, a unique intradermal administration of 
“Rheumavax” (autologous DCs modified with a nuclear factor 
κb inhibitor exposed to 4­citrullinated peptide antigens), was 
studied in a phase I clinical trial of RA patients. They observed a 
significant increased ratio of regulatory to effector T cells and a 
reduction of IL­15, which is a relevant pro­inflammatory cytokine. 
Moreover, in a more clinical level they found a decrease of DAS28 
which is a clinical scale for RA severity together with no disease 
flares (75). Furthermore, in 2017, results from AUTODECRA 
trial (NCT01352858) came out resulting a safe and well tolerated 
therapy with no target knee flares, but with no significant clinical 
and immunomodulatory changes in serum (76).
Importantly, other clinical trials have been recently reported 
in other autoimmune diseases such as Crohn’s disease. In Crohn’s 
disease, our institution conducted a phase I clinical trial to dem­
onstrate the safety of intraperitoneal administration of autologous 
Tol­DCs in refractory patients. The immune monitoring stud­
ies showed an increase of circulating T­regs and a decrease of 
IFN­γ production after T­cell activation (31). Regarding organ 
transplantation, two trials are ongoing. A phase I clinical trial, 
open­label and non­controlled, in liver transplantation is aimed 
to assess the safety of Tol­DCs therapy in this type of patients 
(NCT03164265). The ONEatDC study, aims to assess if Tol­ 
DC administration before renal transplantation is beneficial to 
reduce immunosuppression needs (NCT02252055).
Overall, the encouraging results obtained in above mentioned 
clinical trials, of an increase immunosuppressive activity, drawn 
Tol­DCs as a potential tool to modulate autoinflammatory dis­
eases in the coming years.
ANTigeN-SPeCiFiC THeRAPieS  
iN MS AND NMO
In the recent years, several strategies to modulate antigen­
specific T­cells have been evaluated in therapeutic clinical trials 
for patients with MS and NMO. Among the advantages to use 
antigen­specific therapies, they lack of general immunosuppres­
sion and its side effects as infections and cancer, as well as the 
lack of metabolic activity that activates self­reactive T cells, the 
induction of tolerance to a specific antigen without changing the 
general immunity (77). The use of DC to induce immune toler­
ance is also pursuit in patients with MS and NMO. In this sense, 
a phase I trial to assess the safety of Tol­DC in MS and NMO 
patients in an ascending dose of intravenous administration of 
the DCs (NCT02283671) has been performed at our institution 
and the results are under evaluation. In addition, two more cli­
nical trials are ongoing (NCT02618902) and (NCT02903537), 
which will provide precious information about safety, modulation 
of immune response and clinical efficacy.
Several approaches to induce antigen­specific tolerization 
have been evaluated as DNA vaccination of myelin protein, pep­
tides inoculation, altered peptide ligand (APL) administration 
to modify TCR recognition, autologous myelin­reactive T cells 
administration, HLA/MOG recombinant construct administra­
tion and autologous PBMCs coupled with myelin­peptides 
administration, Tol­DCs with myelin­peptides administration 
(78). Specifically, myelin­peptides approaches are based in a 
myelin relevant immunodominant peptide administration, like 
administration of the synthetic peptide itself like MBP, MOG, or 
PLP, administration of APL or the administration of a region of 
TCR­peptide complex.
Antigen­specific therapeutic approaches have been dem­
onstrated in the majority of the phase I clinical trials to be safe 
and well tolerated. However, a trial conducted at NIH with APL 
induced disease exacerbation and the trial was stopped due to 
safety issues (79). The concept of APL is based in the administra­
tion of modified peptides by introducing some amino acids in 
substitution in specific positions relevant to link with the TCR, but 
8Flórez-Grau et al. Tol-DCs as new antigen-specific Therapy
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1169
without changing the MHC binding part. This strategy is aimed 
to inhibit the inflammatory T  cell response, as acts as partial 
agonist or as antagonist. A phase II trial using MBP83–99 was inter­
rupted as three out of eight participants presented relapses during 
the clinical trial, that were considered as inflammatory activation 
as MRI controls showed disease worsening, and this was corre­
lated with MBP specific T  cell expansion in blood and CSF 
samples (80). Two more trials with APLs were done afterward, 
without objectifying exacerbations of the disease activity (81).
DNA vaccination aims to induce tolerance using heterotopic 
expression of some antigens, for example using whole human 
MBP protein. The BHT­3009 molecule is a union of the whole 
MBP molecule, a human cytomegalovirus promoter and an 
altered plasmid. In two clinical trials it was demonstrated safe 
and gadolinium­enhancing lesions were fewer in the treated 
groups comparing with placebo groups; although, there were 
significant improvement in clinical outcomes. Immunologically, 
a decrease in IFN­γ production and T cell proliferation by MBP, 
PLP, and MOG specific T­cells was observed (82). In another 
trial, reduction of autoreactive T cells was demonstrated with this 
approach, creating a proof of concept of the possible efficacy of 
DNA vaccination (80).
The vaccination with T­cell consists in the administration 
of activated and irradiated MPB­specific T­cell lines and clones 
(attenuated autologous T­cells). Phase I and phase II clinical 
trials have been done, with no relevant side effects, but without 
significant clinical improvement in treated group comparing with 
placebo group (83).
Other antigen­specific tolerization approach studied in MS 
was the antigen­coupled cell tolerance, based on inactivated auto­
logous PBMCs chemically linked with myelin relevant peptides. 
After proving reduction of onset and severity as well as preventing 
epitope spreading in EAE, this approach was evaluated in humans. 
In 2013, a phase I clinical trial (ETIMS trial) was published where 
antigen­specific tolerance induced with inactivated PBMCs cou­
pled with six immunodominant myelin­peptides was safe, with 
some immunological promising results to objectify clinical 
significance (78). Significant advantage of this approach is that 
the tolerization to several myelin relevant peptides derived from 
three different antigens (MBP, MOG, and PLP) simultaneously is 
aimed to prevent the epitope spreading situation.
To synthetize, there are different antigen­specific therapies that 
have been asses in MS patients. The majority has been presented 
as safe and well tolerated with encouraging data regarding the 
clinical benefits.
CONClUSiON AND FUTURe 
PeRSPeCTiveS
Antigen­specific tolerance in autoimmune diseases is a therapeu­
tic approach that is currently been evaluated in MS and NMO 
as well as in other autoimmune diseases. Different reports have 
demonstrated that DCs are powerful therapeutic tools to modify 
the immune response and restore the immune tolerance in ani­
mal models and in preclinical data. Most importantly, the use of 
Tol­DCs in clinical trials is being safe in several phase I clinical 
trials (type I Diabetes, RA and Crohn’s disease) showing in some 
of the studies promising clinical and immunomodulatory results.
In MS several reports have revealed the therapeutic effect of 
Tol­DCs in ameliorating EAE in animal model. These results 
highlight the importance of DCs in the homeostasis control and 
open new avenues for an innovative therapeutic indication for 
human patients. A major challenge is to translate all these results 
obtained in animal models to humans. For that reason, it will be 
crucial to correlate clinical efficacy with modulation of immuno­
logical parameters and also to define the optimal administration 
route, dose of cells, tolerogenic treatments and the potential 
tolerogenic effect of circulating DCs.
From the studies conducted so far, several important consider­
ations have been raised, application of Tol­DCs in humans is safe 
and well tolerated without remarkable side effects and showing 
promising immunological and clinical results. However, phase II 
and/or III clinical trials including control (placebo) group will 
bring some light about the clinical efficacy of this therapy in MS/
NMO patients. In addition, more studies are needed to evaluate 
the real effectiveness and the possibility to use Tol­DC as a real 
treatment for autoimmune diseases.
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